Sensus Healthcare(SRTS) - 2023 Q2 - Quarterly Report

PART I – Financial Information This section presents the unaudited condensed consolidated financial statements and management's discussion and analysis of Sensus Healthcare, Inc Item 1. Condensed Consolidated Financial Statements (unaudited) This section presents the unaudited condensed consolidated financial statements of Sensus Healthcare, Inc. for the period ended June 30, 2023, including the balance sheets, statements of income (loss), stockholders' equity, and cash flows, along with accompanying notes detailing significant accounting policies and specific financial items Condensed Consolidated Balance Sheets (unaudited) This table presents the unaudited condensed consolidated balance sheets, detailing assets, liabilities, and stockholders' equity Financial Data (in thousands) | (in thousands) | June 30, 2023 | December 31, 2022 | | :--- | :--- | :--- | | Assets | | | | Cash and cash equivalents | $20,053 | $25,520 | | Accounts receivable, net | $9,149 | $17,299 | | Inventories | $10,131 | $3,501 | | Total current assets | $47,392 | $53,241 | | Total assets | $52,017 | $56,735 | | Liabilities and stockholders' equity | | | | Total current liabilities | $5,193 | $7,697 | | Total liabilities | $6,007 | $8,666 | | Total stockholders' equity | $46,010 | $48,069 | | Total liabilities and stockholders' equity | $52,017 | $56,735 | - Total assets decreased by $4.7 million from $56.7 million at December 31, 2022, to $52.0 million at June 30, 2023[15] - Total stockholders' equity decreased by $2.0 million from $48.1 million at December 31, 2022, to $46.0 million at June 30, 2023[15] Condensed Consolidated Statements of Income (Loss) (unaudited) This table presents the unaudited condensed consolidated statements of income (loss), showing revenues, gross profit, and net income (loss) Financial Data (in thousands) | (in thousands, except shares and per share data) | Three Months Ended June 30, 2023 | Three Months Ended June 30, 2022 | Six Months Ended June 30, 2023 | Six Months Ended June 30, 2022 | | :--- | :--- | :--- | :--- | :--- | | Revenues | $4,527 | $12,080 | $7,941 | $22,417 | | Gross profit | $2,619 | $8,256 | $4,241 | $15,404 | | Income (loss) from operations | $(1,127) | $4,570 | $(4,065) | $8,498 | | Net income (loss) | $(380) | $3,524 | $(2,274) | $19,586 | | Net income (loss) per share – basic | $(0.02) | $0.21 | $(0.14) | $1.19 | | Net income (loss) per share – diluted | $(0.02) | $0.21 | $(0.14) | $1.17 | - Revenues decreased by 62.8% for the three months ended June 30, 2023, and by 64.7% for the six months ended June 30, 2023, compared to the prior year periods[17] - The Company reported a net loss of $0.38 million for the three months ended June 30, 2023, and $2.27 million for the six months ended June 30, 2023, a significant decline from net income in the prior year periods[17] Condensed Consolidated Statements of Stockholders' Equity (unaudited) This table details changes in stockholders' equity, including common stock, additional paid-in capital, treasury stock, and retained earnings Financial Data (in thousands) | (in thousands, except shares) | Common Stock Shares | Common Stock Amount | Additional Paid-In Capital | Treasury Stock Shares | Treasury Stock Amount | Retained Earnings (Accumulated Deficit) | Total | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | December 31, 2022 | 16,902,761 | $169 | $45,031 | (512,342) | $(3,433) | $6,302 | $48,069 | | Stock-based compensation | - | - | 161 | - | - | - | 161 | | Exercise of stock options | 8,334 | - | 46 | - | - | - | 46 | | Forfeiture of restricted stock units | (7,500) | - | (18) | - | - | - | (18) | | Surrender of shares for tax withholding | - | - | - | (4,487) | (40) | - | (40) | | Net loss | - | - | - | - | - | (1,894) | (1,894) | | March 31, 2023 (unaudited) | 16,913,595 | $169 | $45,220 | (516,829) | $(3,473) | $4,408 | $46,324 | | Stock-based compensation | - | - | 67 | - | - | - | 67 | | Forfeiture of restricted stock units | (1,000) | - | (1) | - | - | - | (1) | | Net loss | - | - | - | - | - | (380) | (380) | | June 30, 2023 (unaudited) | 16,912,595 | $169 | $45,286 | (516,829) | $(3,473) | $4,028 | $46,010 | - Total stockholders' equity decreased from $48.07 million at December 31, 2022, to $46.01 million at June 30, 2023, primarily due to net losses incurred during the period[19] - Stock-based compensation added $228 thousand to additional paid-in capital during the six months ended June 30, 2023[19] Condensed Consolidated Statements of Cash Flows (unaudited) This table presents the unaudited condensed consolidated statements of cash flows, categorizing cash movements from operating, investing, and financing activities Financial Data (in thousands) | (in thousands) | Six Months Ended June 30, 2023 | Six Months Ended June 30, 2022 | | :--- | :--- | :--- | | Net cash provided by (used in) operating activities | $(5,255) | $4,978 | | Net cash provided by (used in) investing activities | $(218) | $14,911 | | Net cash provided by (used in) financing activities | $6 | $(705) | | Net increase (decrease) in cash and cash equivalents | $(5,467) | $19,184 | | Cash and cash equivalents – end of period | $20,053 | $33,703 | - Net cash used in operating activities was $5.26 million for the six months ended June 30, 2023, a significant change from $4.98 million provided in the prior year period[22] - Net cash used in investing activities was $0.22 million for the six months ended June 30, 2023, compared to $14.91 million provided in the prior year, which included proceeds from asset sales[22] Notes to the Condensed Consolidated Financial Statements (unaudited) These notes provide detailed information on the Company's organization, significant accounting policies, and specific financial statement line items - Sensus Healthcare, Inc. is primarily a manufacturer of radiation therapy devices, operating in one segment globally[24] - Revenue is recognized upon transfer of control of goods or services, with service contract revenues recognized over the contract period on a straight-line basis[30][32] Disaggregated Revenue (in thousands) | Revenue Type | Three Months Ended June 30, 2023 | Three Months Ended June 30, 2022 | Six Months Ended June 30, 2023 | Six Months Ended June 30, 2022 | | :--- | :--- | :--- | :--- | :--- | | Product Revenue - recognized at a point in time | $3,524 | $10,970 | $5,993 | $20,199 | | Service Revenue - recognized at a point in time | $306 | $205 | $647 | $524 | | Service Revenue - recognized over time | $697 | $905 | $1,301 | $1,694 | | Total Revenue | $4,527 | $12,080 | $7,941 | $22,417 | - One U.S. customer accounted for 46% and 52% of revenue for the three and six months ended June 30, 2023, respectively, and 86% of accounts receivable as of June 30, 2023, indicating significant customer concentration[38] Revenue by Geographic Region (in thousands) | Region | Three Months Ended June 30, 2023 | Three Months Ended June 30, 2022 | Six Months Ended June 30, 2023 | Six Months Ended June 30, 2022 | | :--- | :--- | :--- | :--- | :--- | | United States | $3,892 (86%) | $11,349 (94%) | $7,166 (90%) | $21,497 (96%) | | China | $300 (7%) | $711 (6%) | $430 (5%) | $890 (4%) | | Guatemala | $190 (4%) | - (0%) | $190 (2%) | - (0%) | | Ireland | $135 (3%) | - (0%) | $135 (2%) | - (0%) | | Other | $10 (0%) | $20 (0%) | $20 (0%) | $30 (0%) | | Total Revenue | $4,527 (100%) | $12,080 (100%) | $7,941 (100%) | $22,417 (100%) | - The allowance for expected credit losses on accounts receivable decreased from $107 thousand at December 31, 2022, to $28 thousand at June 30, 2023[46] - The Company had a revolving credit facility with Silicon Valley Bank (now First-Citizens Bank & Trust Company) with $15 million available borrowings at June 30, 2023, and was in compliance with covenants, with no outstanding borrowings[59][61][62] Product Warranty Liability (in thousands) | Item | Amount | | :--- | :--- | | Balance, December 31, 2022 | $403 | | Warranties accrued during the period | $281 | | Payments on warranty claims | $(305) | | Balance, June 30, 2023 | $379 | - The Company leases its headquarters office under an operating lease expiring in September 2027, with a weighted-average remaining lease term of 4.25 years and a weighted-average discount rate of 5%[65][67] - Purchases from the primary contract manufacturer totaled $1.2 million and $7.9 million for the three and six months ended June 30, 2023, respectively[70] - The Company is involved in a Department of Justice investigation regarding physician billing to Medicare for its SRT-100 product, but disputes any wrongdoing and is unable to estimate associated costs[72] - Unrecognized stock compensation expense was $557 thousand as of June 30, 2023, to be recognized over a weighted average period of 3 years[81] Income Tax (Benefit) Expense (in thousands) | Period | Income Tax (Benefit) Expense | | :--- | :--- | | Three Months Ended June 30, 2023 | $(502) | | Three Months Ended June 30, 2022 | $1,070 | | Six Months Ended June 30, 2023 | $(1,303) | | Six Months Ended June 30, 2022 | $1,718 | - The effective tax rate for the three months ended June 30, 2023, was 56.9%, up from 23.3% in the prior year, primarily due to an increase in non-deductible expenses relative to pretax book income[89] Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations This section provides management's perspective on the Company's financial performance and condition, highlighting significant changes in revenues, expenses, and key balance sheet items, and discussing liquidity and capital resources Overview This section provides a general description of Sensus Healthcare's business and strategic focus - Sensus is a medical device company focused on providing non-invasive and cost-effective treatments for oncological and non-oncological skin conditions[94] Segment Information This section details the Company's operating segments and how they are managed - The Company manages its business globally within one reportable segment[95] Results of Operations This section analyzes the Company's financial performance, including revenues, costs, and profitability trends Key Financial Results (in thousands) | Metric | 3 Months Ended June 30, 2023 | 3 Months Ended June 30, 2022 | Change (%) | 6 Months Ended June 30, 2023 | 6 Months Ended June 30, 2022 | Change (%) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Revenues | $4,527 | $12,080 | -62.8% | $7,941 | $22,417 | -64.7% | | Cost of sales | $1,908 | $3,824 | -50.0% | $3,700 | $7,013 | -47.1% | | Gross profit | $2,619 | $8,256 | -68.7% | $4,241 | $15,404 | -72.7% | | Income (loss) from operations | $(1,127) | $4,570 | N/A | $(4,065) | $8,498 | N/A | | Net income (loss) | $(380) | $3,524 | N/A | $(2,274) | $19,586 | N/A | - The decrease in revenues for both periods was primarily due to a lower number of SRT units sold and reduced sales to a large customer, as customers deferred purchases[97][103] - Gross profit percentage decreased to 57.8% for the three months ended June 30, 2023 (from 68.6% in 2022) and to 53.2% for the six months ended June 30, 2023 (from 68.6% in 2022), driven by lower unit sales and higher vendor costs[99][105] - Selling and marketing expenses decreased by 5.9% for the three-month period but increased by 27.6% for the six-month period, mainly due to increased tradeshow and advertising expenses[100][106] - Research and development expenses increased by 18.8% for the six-month period, primarily due to a project to develop a drug delivery system for an aesthetic project, expected to be completed by the end of 2023[108] - Other income for the six months ended June 30, 2022, included a significant $12.8 million gain on the sale of Sculptura assets, which was not present in 2023[109] Financial Condition This section discusses key changes in the Company's balance sheet items and overall financial position - Cash and cash equivalents decreased by $5.4 million from December 31, 2022, to June 30, 2023[111] - Accounts receivable decreased by $8.2 million, mainly due to collections and lower sales[111] - Inventories increased by $6.6 million, primarily due to an increase in finished goods completion[112] - Prepaid and other assets increased by $1.1 million, mainly due to an increased deposit paid to a manufacturer[112] Liquidity and Capital Resources This section evaluates the Company's ability to generate and manage cash, and its sources of funding Summary of Cash Flows (in thousands) | Activity | Six Months Ended June 30, 2023 | Six Months Ended June 30, 2022 | | :--- | :--- | :--- | | Operating activities | $(5,255) | $4,978 | | Investing activities | $(218) | $14,911 | | Financing activities | $6 | $(705) | | Total | $(5,467) | $19,184 | - Net cash used in operating activities was $5.3 million for the six months ended June 30, 2023, driven by a net loss and an increase in net operating liabilities[116] - Net cash used in investing activities was $0.2 million, primarily for property and equipment acquisitions, contrasting with $15 million provided in the prior year from asset sales[117] - The Company's short-term capital needs include expenditures for expanding sales, marketing, and R&D activities[115] Indebtedness This section outlines the Company's debt obligations and credit facilities - There were no borrowings outstanding under the Company's revolving line of credit at June 30, 2023, or December 31, 2022[114] Contractual Obligations and Commitments This section describes the Company's significant contractual obligations and future commitments - The Company has a contract manufacturing agreement for its SRT-100 products and is involved in legal proceedings, including a Department of Justice investigation[69][72][120] Critical Accounting Policies and Estimates This section highlights the accounting policies and estimates that require significant management judgment - The preparation of financial statements requires management to make estimates and assumptions that affect reported amounts, with actual results potentially differing significantly[121] Item 3. Quantitative and Qualitative Disclosures about Market Risk This section states that the Company has no applicable quantitative and qualitative disclosures about market risk for the reporting period - The Company has no applicable quantitative and qualitative disclosures about market risk[122] Item 4. Controls and Procedures Management, including the CEO and CFO, concluded that the Company maintained effective disclosure controls and procedures as of June 30, 2023, and reported no significant changes in internal control over financial reporting during the quarter - Management, including the CEO and CFO, concluded that disclosure controls and procedures were effective as of June 30, 2023[123] - There were no significant changes in internal control over financial reporting during the most recently completed fiscal quarter[124] PART II – Other Information This section provides supplementary information including legal proceedings, risk factors, equity sales, and other disclosures Item 1. Legal Proceedings The Company is involved in certain legal proceedings in the ordinary course of business, as detailed in Note 7 to the financial statements - The Company is a party to certain legal proceedings in the ordinary course of business, as further described in Note 7, Commitments and Contingencies[127] Item 1A. Risk Factors This section refers readers to the risk factors discussed in the Company's 2022 Annual Report on Form 10-K and subsequent quarterly reports, noting that additional unknown or immaterial risks could also adversely affect the business - Readers should consider risk factors from the 2022 Annual Report and subsequent quarterly reports[128] - Additional unknown or currently immaterial risks may materially adversely affect the Company's business, financial condition, or operating results[128] Item 2. Unregistered Sales of Equity Securities and Use of Proceeds The Company reported no unregistered sales of equity securities, no use of proceeds from registered securities sales, and no purchases of equity securities by the registrant or affiliated purchasers during the six months ended June 30, 2023 - There were no unregistered sales of securities during the six months ended June 30, 2023[129] - There was no use of proceeds from the sale of registered securities[130] - No purchases of equity securities by the registrant and affiliated purchasers occurred[131] Item 3. Defaults Upon Senior Securities The Company reported no defaults upon senior securities for the period - There were no defaults upon senior securities[131] Item 4. Mine Safety Disclosure This item is not applicable to the Company - Mine Safety Disclosure is not applicable to the Company[132] Item 5. Other Information No directors or officers adopted or terminated any Rule 10b5-1 trading plans or non-Rule 10b5-1 trading arrangements during the three months ended June 30, 2023 - No directors or officers adopted or terminated any Rule 10b5-1 trading plans or non-Rule 10b5-1 trading arrangements during the three months ended June 30, 2023[133] Item 6. Exhibits This section lists all exhibits filed with the Form 10-Q, including employment agreements, certifications from the CEO and CFO, and Inline XBRL documents Key Exhibits Filed | Exhibit No. | Description | | :--- | :--- | | 10.1 | Employment Agreement between Sensus Healthcare, Inc. and Javier Rampolla | | 31.1 | Certification of Joseph C. Sardano, Chairman and Chief Executive Officer | | 31.2 | Certification of Javier Rampolla, Chief Financial Officer | | 32.1 | Certification of Joseph C. Sardano, Chairman and Chief Executive Officer, Pursuant to 18 U.S.C. Section 1350 | | 32.2 | Certification of Javier Rampolla, Chief Financial Officer, Pursuant to 18 U.S.C. Section 1350 | | 101.INS | Inline XBRL Instance Document | | 104 | Cover Page Interactive Data File | Signatures This section contains the official signatures of the Company's authorized officers, certifying the report's accuracy - The report was signed by Joseph C. Sardano, Chief Executive Officer, and Javier Rampolla, Chief Financial Officer, on August 11, 2023[139]